Home Health Novo Nordisk expands focus to heart problems as fortunes soar on Wegovy – ET HealthWorld | Pharma

Novo Nordisk expands focus to heart problems as fortunes soar on Wegovy – ET HealthWorld | Pharma

Novo Nordisk expands focus to heart problems as fortunes soar on Wegovy – ET HealthWorld | Pharma


By Jacob Gronholt-Pedersen and Maggie Fick

Copenhagen: Novo Nordisk, its fortunes hovering on gross sales of its weight problems drug Wegovy, stated on Thursday it was increasing its give attention to diabetes and weight-loss therapies to incorporate heart problems therapies.

CEO Lars Fruergaard Jorgensen, talking because the Danish firm hosts buyers and analysts at its headquarters close to Copenhagen, made the announcement within the firm’s first technique replace since Wegovy exploded in recognition.

Jorgensen stated Novo was altering its company technique to switch “different critical continual illness” as a spotlight space with an specific concentrating on of heart problems.

The change comes after the drugmaker final August stated a big research had proven Wegovy additionally had a transparent cardiovascular profit, boosting efforts by the corporate to maneuver Wegovy past its picture as a way of life drug.

“We have put intensive work into constructing a aggressive pipeline in heart problems,” Novo’s head of company improvement David Moore advised buyers.

“It is an adjacency however it aligns effectively with our historical past in diabetes and weight problems,” he stated.

Wegovy is a part of a category of medication that mimic a intestine hormone, GLP-1, that helps regulate blood sugar and urge for food.

The cardiovascular advantages of the drug have stirred a debate about whether or not the long-term medical advantages of weight-loss medication are sufficient to scale back the general burden on healthcare techniques and the price of treating coronary heart illness in obese and overweight folks.

Moore stated Novo would search to “maximise” improvement of its first standalone heart problems compound, ziltivekimab, which is at the moment in Part 3 improvement for therapy of atherosclerotic cardiovascular disease in folks residing with chronic kidney disease.

In an period of unprecedented ranges of weight problems worldwide, Wegovy has reworked drugmaker Novo, lengthy often called a maker of insulin.

Novo’s market capitalisation stood at about $560 billion going into the capital markets day in contrast with round $235 billion two years in the past when it final held an investor day.

Noveo shares have been up 1.3 per cent at 0843 GMT, shortly after the capital markets day started. They’re up round 15 per cent because the firm reported full-year earnings on Jan. 31, and have risen greater than three-fold since June 2021 when it launched Wegovy in the US.

(Reporting by Maggie Fick, Jacob Gronholt-Pedersen, Louise Breusch Rasmussen, and Stine Jacobsen in Copenhagen; Modifying by Terje Solsvik and Emelia Sithole-Matarise)

  • Printed On Mar 8, 2024 at 10:38 AM IST

Be part of the group of 2M+ business professionals

Subscribe to our publication to get newest insights & evaluation.

Obtain ETHealthworld App

  • Get Realtime updates
  • Save your favorite articles

Scan to obtain App


Source link


Please enter your comment!
Please enter your name here